These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 28591560)
21. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Willier S; Butt E; Grunewald TG Biol Cell; 2013 Aug; 105(8):317-33. PubMed ID: 23611148 [TBL] [Abstract][Full Text] [Related]
22. Autotaxin-Lysophosphatidic Acid: From Inflammation to Cancer Development. Valdés-Rives SA; González-Arenas A Mediators Inflamm; 2017; 2017():9173090. PubMed ID: 29430083 [TBL] [Abstract][Full Text] [Related]
24. ATX-LPA axis induces expression of OPN in hepatic cancer cell SMMC7721. Zhang R; Zhang Z; Pan X; Huang X; Huang Z; Zhang G Anat Rec (Hoboken); 2011 Mar; 294(3):406-11. PubMed ID: 21337710 [TBL] [Abstract][Full Text] [Related]
25. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme. Tabuchi S Lipids Health Dis; 2015 Jun; 14():56. PubMed ID: 26084470 [TBL] [Abstract][Full Text] [Related]
26. The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer. Teo K; Brunton VG Biochem J; 2014 Oct; 463(1):157-65. PubMed ID: 25195735 [TBL] [Abstract][Full Text] [Related]
28. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression? Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736 [TBL] [Abstract][Full Text] [Related]
29. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341 [TBL] [Abstract][Full Text] [Related]
30. Plasma Concentrations of Lysophosphatidic Acid and Autotaxin in Abstinent Patients with Alcohol Use Disorder and Comorbid Liver Disease. Flores-López M; García-Marchena N; Pavon FJ; Lara E; Porras-Perales O; Araos P; Requena-Ocaña N; Torres-Galván S; Mañas-Padilla MC; Rubio G; Suárez J; Santín LJ; Rodríguez de Fonseca F; Castilla-Ortega E; García-Fernández MI; Serrano A Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572393 [TBL] [Abstract][Full Text] [Related]
31. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. Streba LA; Vere CC; Rogoveanu I; Streba CT World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859 [TBL] [Abstract][Full Text] [Related]
38. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Panupinthu N; Lee HY; Mills GB Br J Cancer; 2010 Mar; 102(6):941-6. PubMed ID: 20234370 [TBL] [Abstract][Full Text] [Related]
39. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Torres DM; Harrison SA Semin Liver Dis; 2012 Feb; 32(1):30-8. PubMed ID: 22418886 [TBL] [Abstract][Full Text] [Related]
40. Steatohepatitic hepatocellular carcinoma, a morphologic indicator of associated metabolic risk factors: a study from India. Jain D; Nayak NC; Kumaran V; Saigal S Arch Pathol Lab Med; 2013 Jul; 137(7):961-6. PubMed ID: 23808468 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]